These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 14994922)

  • 21. Clinical relationship between MDR1 gene and gallbladder cancer.
    Wang BL; Zhai HY; Chen BY; Zhai SP; Yang HY; Chen XP; Zhao WT; Meng L
    Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):296-9. PubMed ID: 15138130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines.
    Fantappiè O; Solazzo M; Lasagna N; Platini F; Tessitore L; Mazzanti R
    Cancer Res; 2007 May; 67(10):4915-23. PubMed ID: 17510421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic efficacy and bone marrow protection of the mdr1 gene and over-dose chemotherapy with doxorubicin for rabbits with VX2 hepatocarcinoma.
    Wang Y; Jin XQ; Wang S; Wang Q; Luo Q; Luo XJ
    Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):545-51. PubMed ID: 17085340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines.
    Lasagna N; Fantappiè O; Solazzo M; Morbidelli L; Marchetti S; Cipriani G; Ziche M; Mazzanti R
    Cancer Res; 2006 Mar; 66(5):2673-82. PubMed ID: 16510587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversal of cancer multidrug resistance by green tea polyphenols.
    Mei Y; Qian F; Wei D; Liu J
    J Pharm Pharmacol; 2004 Oct; 56(10):1307-14. PubMed ID: 15482646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of lung resistance-related protein in transitional cell carcinoma of bladder.
    Zhu Y; Kong C; Zeng Y; Sun Z; Gao H
    Urology; 2004 Apr; 63(4):694-8. PubMed ID: 15072883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hypoxia-inducible factor-1 alpha dependent expression and significance of the related multidrug resistance genes induced by hypoxia in human hepatocarcinoma cell].
    Zhu H; Chen XP; Luo SF; Guan J; Zhang WG; Zhang BX; Wang HP
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(5):277-81. PubMed ID: 15842930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of HCC drug resistance by using hammerhead ribozymes against multidrug resistance 1 gene.
    Qia S; Wang H; Chen X
    J Huazhong Univ Sci Technolog Med Sci; 2005; 25(6):662-4. PubMed ID: 16696319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug Resistance in Hepatocellular Carcinoma: Theoretical Basis and Therapeutic Aspects.
    Lei YR; He XL; Li J; Mo CF
    Front Biosci (Landmark Ed); 2024 Feb; 29(2):52. PubMed ID: 38420802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of chemotherapy resistance in cancer treatment.
    Deisseroth AB; Pizzorno G
    Cancer J Sci Am; 1997; 3(2):60-9. PubMed ID: 9099453
    [No Abstract]   [Full Text] [Related]  

  • 31. Molecular bases of the poor response of liver cancer to chemotherapy.
    Marin JJG; Briz O; Herraez E; Lozano E; Asensio M; Di Giacomo S; Romero MR; Osorio-Padilla LM; Santos-Llamas AI; Serrano MA; Armengol C; Efferth T; Macias RIR
    Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):182-192. PubMed ID: 29544679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mismatch repair defects as a cause of resistance to cytotoxic drugs.
    Irving JA; Hall AG
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):149-58. PubMed ID: 12113123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene therapy of hepatocarcinoma: a long way from the concept to the therapeutical impact.
    Gérolami R; Uch R; Bréchot C; Mannoni P; Bagnis C
    Cancer Gene Ther; 2003 Sep; 10(9):649-60. PubMed ID: 12944984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Giant Lysosomes as a Chemotherapy Resistance Mechanism in Hepatocellular Carcinoma Cells.
    Colombo F; Trombetta E; Cetrangolo P; Maggioni M; Razini P; De Santis F; Torrente Y; Prati D; Torresani E; Porretti L
    PLoS One; 2014; 9(12):e114787. PubMed ID: 25493932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of sirtuins in hepatocellular carcinoma progression and multidrug resistance: Mechanistical and pharmacological perspectives.
    Ceballos MP; Quiroga AD; Palma NF
    Biochem Pharmacol; 2023 Jun; 212():115573. PubMed ID: 37127248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anthracycline resistance.
    Friche E; Skovsgaard T; Nissen NI
    Acta Oncol; 1989; 28(6):877-81. PubMed ID: 2692650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thinking small, doing big: Current success and future trends in drug delivery systems for improving cancer therapy with special focus on liver cancer.
    Limeres MJ; Moretton MA; Bernabeu E; Chiappetta DA; Cuestas ML
    Mater Sci Eng C Mater Biol Appl; 2019 Feb; 95():328-341. PubMed ID: 30573256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advanced technological tools to study multidrug resistance in cancer.
    Andrei L; Kasas S; Ochoa Garrido I; Stanković T; Suárez Korsnes M; Vaclavikova R; Assaraf YG; Pešić M
    Drug Resist Updat; 2020 Jan; 48():100658. PubMed ID: 31678863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of Therapy Response and Prognosis in Leukemias by Flow Cytometric MDR Assays.
    Kappelmayer J; Hevessy Z; Apjok A; Jakab KT
    EJIFCC; 2013 Jan; 23(4):117-23. PubMed ID: 27683427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of multiple drug resistance (MDR) proteins on chemotherapy and drug discovery.
    Skatrud PL
    Prog Drug Res; 2002; 58():99-131. PubMed ID: 12079203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.